Sjögren's disease & overlap diseases
Clinical and molecular characterization of interstitial lung disease (ILD) in patients with overlapping anti-synthetase syndrome (ASyS) and SjD: a retrospective observational study
Authors' conclusion
ASyS-SjD exhibits an ASyS-like clinical phenotype with additional profibrotic features, suggesting it may represent an overlap subtype rather than a coincidental coexistence. While ILD in ASyS-SjD appears more aggressive than in SjD, it is not clearly more severe than in ASyS.
Study context
- Population
- Patients with ASyS, Primary Sjögren's Disease (pSjD) or overlapping ASyS-SjD, First Affiliated Hospital of Nanjing Medical University, June 2020–June 2023
- Participants
- 42 / 78 / 131
- Exposure
- ASyS-SjD vs pSjD and vs ASyS
- ASyS-SjDn = 42
- pSjDn = 78reference
- ASySn = 131
- Outcome
- Clinical features of ILD in ASyS-SjD vs pSjD
Methodological detailssingle-centre, RNA sequencing of PBMCs
- Single-centre
- RNA sequencing of PBMCs
Main finding
As reported in the abstract
- ASyS-SjD
- Time to ILD onset (months) 10.0 vs 67.5 months; P < 0.001
- ASyS-SjD
- RP-ILD 16.7% vs 3.9%; P = 0.015
- ASyS-SjD
- FEV1% 63.5% vs 76.6%; P = 0.010
- ASyS-SjD
- FVC% 64.2% vs 77.0%; P = 0.024
- ASyS-SjD
- DLCO% 60.7% vs 72.6%; P = 0.046
Observational data: associations, not effects.
Further findings
HRCT pattern in ASyS-SjD
- NSIP (predominant, similar to ASyS)
- 75.6%
- LIP
- 2.4%
PBMC transcriptomics (8 ASyS, 9 pSjD, 10 ASyS-SjD, 10 controls)
- Shared inflammation with ASyS plus unique profibrotic signalling in ASyS-SjD
Original publication
Clinical and molecular characterization of ILD in patients with overlapping ASyS and SjD: a retrospective observational study. Rheumatology (Oxford). Published 29 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →